• The shortest isoform of C/EBPb, liver inhibitory protein (LIP), collaborates with Evi1 in leukemogenesis.
Introduction
Ecotropic viral integration site 1 (Evi1), which is located on chromosome 3q26, is one of the critical regulators of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Several clinical studies have indicated that inappropriate expression of Evi1 is found in 10% of patients with AML regardless of 3q26 abnormalities, and that high expression of Evi1 is associated with poor prognosis. [1] [2] [3] Evi1 was originally identified in a common integration site of murine leukemia retrovirus, and enhanced expression of Evi1 by retrovirus integration is thought to be responsible for leukemogenesis in mouse models. 4 However, retroviral expression of marker genes such as CD34 has not induced hematologic malignancy even if some clones possessing integration at the Evi1 site have been identified. 5 Accordingly, so far we have not found hematologic abnormalities in mice transplanted with bone marrow (BM) cells, which have been transduced with green fluorescent protein (GFP) as a control.
In a case study, 2 patients with X-chronic granulomatous disease (X-CGD), who underwent gene therapy using retrovirus, went on to have myelodysplasia and myeloid leukemia with monosomy 7 as a result of insertional activation of Evi1. 6 The cases suggested that overexpression of Evi1 in human cells induced genomic instability and caused additional genetic change, such as monosomy 7 followed by AML.
These reports indicate that Evi1 requires cooperative factors to induce AML, whereas overexpression of Evi1 is enough to lead to clonal expansion of hematopoietic cells. Therefore, identifying genes collaborating with Evi1 in leukemogenesis is one of the key issues in understanding Evi1-related leukemia.
In our previous work, we demonstrated that a point mutation of the transcription factor AML1 (AML1-D171N) induces MDS that progresses to AML in association with overexpression of Evi1 through a mouse BM transplantation (BMT) model. 7 Recently, we succeeded in making a mouse model of Evi1-induced leukemia by using retroviral transduction of Evi1 and observed that all of the mice went on to have AML within 6 to 11 months after transplantation. 8 We supposed that retroviral enhancers would have some effects on the initiation of leukemia in our Evi1-leukemia model mice. Regarding retroviral integration sites, we identified frequent retroviral integrations at the 39 side of the C/EBPb gene in the Evi1-transduced leukemic cells. These results suggest that C/EBPb is a candidate gene that collaborates with Evi1 in leukemogenesis. C/EBPb, also known as NF-IL6, is a transcription factor that specifically binds to an interleukin (IL)1-responsive element in the IL-6 gene and has a role in regulation not only for the IL-6 gene but also for several cytokine genes such as tumor necrosis factor, IL-8, and granulocyte colony-stimulating factor (G-CSF). 9 The locus of the C/EBPb gene has been reported as a common integration site in the Retrovirus Tagged Cancer Gene Database (RTCGD), 10 which is a database of retroviral insertional mutagenesis in mouse tumors. Furthermore, C/EBPb collaborates with PRDM16, also named the MDS1/EVI1-like gene, in initiation of a differentiation switch from myoblasts to brown fat cells. 11 Therefore, in this study, we examined the effect of C/EBPb on the development of leukemia and a close collaboration of Evi1 and C/ EBPb in leukemogenesis. Our data raise the possibility that targeting the C/EBPb pathway may provide a new strategy for the treatment of Evi1-related leukemia. Furthermore, this novel mouse model may be useful for the development of effective treatments of patients with AML/MDS in which Evi1 is highly expressed.
Materials and methods

Vector construction
The pMYs-mouse Evi1-IG was provided by Dr. Takuro Nakamura (the Cancer Institute, Tokyo, Japan), and the pcDNA-mouse Evi1 was provided by Dr. Kazuhiro Morishita (the University of Miyazaki, Miyazaki, Japan). We used 3 isoforms of C/EBPb: liver activating protein* (LAP*, one of the long isoforms), liver activating protein (LAP, the other long isoform), and liver inhibitory protein (LIP, a short isoform). The coding regions of LAP* and LIP were amplified by reverse transcription (transcriptase)-polymerase chain reaction (RT-PCR) using complementary DNA (cDNA) derived from mouse BM cells. The LAP* cDNA contains all 3 initiation codons (methionine) (ATGs) for LAP*, LAP, and LIP. LAP was obtained from pcDNA 3.1-mouse C/EBPb (Addgene, Cambridge, MA). The LAP cDNA contains 2 ATGs for LAP and LIP. The LIP cDNA contains 1 ATG for LIP. All of the isoforms were inserted to a pGCDNsam-IRES-Kusabira Orange vector 12 to generate pGCDNsam-LAP*, LAP, or LIP-Kusabira Orange, respectively. Plasmid constructs containing the mouse C/EBPb promoter (23.5 kb from the first ATG) were prepared by PCR amplification using cDNA derived from C57BL/6 mouse peripheral blood (PB) cells as a template, and the PCR products were cloned into the pGL4.10 [luc2] luciferase vector (Promega, Madison, WI).
Transfection and retrovirus production
PLAT-E 13 packaging cells were transfected with retroviral constructs by using FuGENE 6 (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's recommendations, and retroviruses were harvested as described previously. 14 Mouse BMT and analysis of the transplanted mice BM mononuclear cells were isolated from donor mice (age 8 weeks, C57BL/6 (Ly-5.1) or C/EBPb conditional knockout mice). The BM cells were infected with retroviruses using RetroNectin (Takara Bio, Japan) according to the manufacturer's recommendations. For double infection, we mixed 2 virus suspensions with an equal ratio. The infected BM cells (derived from Ly-5.1 or C/EBPb conditional knockout mice) were injected through the tail vein into C57BL/6 (Ly-5.2) recipient mice (age 8-9 weeks), which had been administered a sublethal dose of 5.25 Gy of total-body g-irradiation (supplemental Methods). Engraftment was confirmed by measuring the percentage of Ly-5.1 and GFP and/or Kusabira Orange-positive cells in the PB. If a recipient mouse were physically inactive such as showing breathing difficulties, exhibiting weight loss, having a low body temperature, or sitting in a hunched position, the mouse was euthanized for analysis. To assess whether the leukemic cells were transplantable, 2 3 10 5 2 1 3 10 6 whole BM cells, including blasts, were injected into sublethally irradiated mice through the tail veins. All animal studies were approved by the Animal Care Committee of the University of Tokyo.
Flow cytometric analysis and cell sorting
Flow cytometric analysis was performed on FACSLSRII flow (BD Biosciences), equipped with CellQuest software (BD Biosciences), and analyzed using FlowJo software (Tree Star, San Carlos, CA). We used FACSAria II (BD Biosciences) for cell sorting. Human CD34 1 cells were sorted by autoMACS (Miltenyi Biotec, Germany) using CD34-PE conjugated antibody (Beckman Coulter, CA) and anti-PE MicroBeads (Miltenyi Biotec, Germany) according to the manufacturer's instructions.
Human samples
Written informed consent was obtained from all patients whose samples were collected after the ethical guidelines for biomedical research involving human subjects came into force. We used whole BM cells derived from patients diagnosed with primary immune thrombocytopenia or lymphoma without BM invasion as controls, with written informed consent in accordance with the Declaration of Helsinki. Human CD34 1 and CD34 2 cells were obtained from BM or from the residual PB stem cells harvested for autologous transplantation.
Diagnosis
Diagnosis was made according to the Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice 15 and the leukemia diagnosis in murine BMT models. 16 Colony assay BM cells (1.0 3 10 4 cells) in methylcellulose M3434 medium (StemCell Technologies, Vancouver, Canada) were plated in duplicate in 35-mm petri dishes. The number of colonies was scored after 7 days, and 1.0 3 10 4 cells recovered from the cultured plates were replated every 7 days.
Real-time RT-PCR
Total RNA of human BM samples was extracted using ISOGEN (Nippon Gene, Tokyo, Japan). Total RNA of mouse BM cells was extracted using Trizol (Invitrogen, CA). cDNA was prepared with the Superscript III RT kit (Invitrogen) or Transcriptor 1st strand cDNA synthesis kit (Roche Diagnostics, Mannheim, Germany). Real-time RT-PCR was performed using a LightCycler 480 Real-Time PCR System and Light Cycler 2.0 instrument (Roche Diagnostics). cDNA was amplified using a SYBR Premix EX Taq (TAKARA, Japan), LightCycler FastStart Reaction Mix SYBR Green I (Roche Diagnostics), and a LightCycler FastStart DNA Master Hybridization probe (Roche Diagnostics). The primer pairs are shown in supplemental Table 1 . Expression levels were normalized by the expression level of 18S ribosomal RNA (rRNA).
Western blot analysis
Spleen cells of leukemic mice, human whole BM cells from patients, and CD34 1 and CD34 2 control cells were lysed with TNE buffer. Equal amounts of total cell lysates were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis and were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA). The following antibodies were used: monoclonal rabbit anti-Evi1 antibody (Cell Signaling, Danvers, MA), a monoclonal mouse anti-Flag M2 antibody (Sigma, St. Louis, MO) for Evi1, a monoclonal rabbit anti-C/EBPb antibody (C-19; Santa Cruz Biotechnology, Santa Cruz, CA), a monoclonal rabbit anti-C/EBPa antibody (14AA; Santa Cruz Biotechnology), and a monoclonal rabbit anti-b-actin antibody (Cell Signaling). Images were recorded using the luminescent image analyzer (LAS-3000; Fujifilm), and the intensities of the bands were quantitated by densitometry using Multi Gauge Version 3.0 software (Fujifilm). See supplemental Methods for details about the protein complex immunoprecipitation assay.
Southern blot analysis
Genomic DNA was extracted from spleen cells. Enzymatic digestion of 10 mg of DNA with EcoRI was followed by electrophoretic separation and overnight transfer to Hybond N nylon membrane; then proviruses were probed with a GFP probe. To examine the clonality of the leukemic cells with retroviral integration near the C/EBPb locus, genomic DNA was digested with BamHI, separated by electrophoration, and then transferred to Hybond N nylon membrane overnight. Probes that lie in the vicinity of the integration sites were made by PCR purification and TA cloning. Primer and probe sequences are shown in supplemental Table 2 and 3.
Bubble PCR
The bubble PCR method was performed as described previously 7, 17, 18 (supplemental Methods). Briefly, 10 mg of genomic DNA extracted from spleen cells were digested with EcoRI or BamHI, and the fragments were ligated to a double-stranded bubble linker. Next, PCR was performed on the ligation product using a linker-specific Vectorette primer and an LTRspecific primer. The PCR product was sequenced to identify the retrovirus integration sites. We confirmed the inverse repeated sequence "GGGG GTCTTTCA" as a junction marker between the genomic DNA and the retrovirus sequence. Sequence data are shown in supplemental Table 2 .
Luciferase assay
To examine the possibility of transcriptional activation of C/EBPb by Evi1, a luciferase assay was performed using the reporter plasmid (pGL4-C/ EBPb 3.5k) and the effector plasmid (pcDNA-mouse Evi1). See supplemental Methods for details.
Conditional ablation of C/EBPb
C/EBPb conditional knockout mice, which have alleles of C/EBPb flanking the coding region with LoxP recombination sites, were obtained from Dr. Sterneck at the National Cancer Institute. 19 The C/EBPb fl/fl mice were mated to Mx-Cre transgenic mice. 20 We use the term "Mx-Cre;C/EBPb fl/fl " for this mice. To excise the C/EBPb locus, we performed intraperitoneal injection of 400-ug/body pI-pC three or five times. Excision of the C/EBPb coding region was confirmed in genomic DNA from PB or BM cells by PCR analysis (supplemental Methods). The fragment should be 162 bp for the wild-type allele, 210 bp for the floxed allele, and 72 bp for the deleted allele.
Results
A high incidence of retroviral integration close to the site of the C/EBPb gene was observed in Evi1-leukemic mice
We succeeded in establishing a mouse model of Evi1-leukemia ( Figure 1A ). 8 As we have reported previously, the Evi1-mice appeared healthy until 5 months after transplantation, but the number of GFP-positive-Evi12expressing cells gradually increased in the PB, and the mice died at 6 to 11 months after transplantation ( Figure 1B ). We confirmed that the leukemic cells were transplantable. We wondered if retroviral enhancers might have influenced the induction of leukemia in our model mice, because the long latencies suggested clonal selection in leukemic transformation of primary BM cells.
First, we examined a number of clones in the leukemic mice by Southern blotting using a GFP probe. As shown in Figure1C, the leukemic cells were monoclonal or oligoclonal. Next, we examined the retroviral integration site of these leukemic cells by using the bubble PCR method. Surprisingly, we identified frequent integration near the C/EBPb gene in 6 of 10 mice transplanted with Evi1-transduced BM cells ( Figure 1D -E and Table 1 ). Because retroviral integration to the C/EBPb locus has not been observed in our previous study, 7, 21 Evi1-induced leukemic mice had a high frequency of integration in the C/EBPb locus with statistical significance compared with other types of leukemic mice (supplemental Table 4 ; P 5 .00024, Fisher exact test). The integrations were located at 62.5-86.7 kb downstream from the C/EBPb gene ( Figure 1F ). We investigated the integration site in the serially transplanted leukemic cells and confirmed the identical integration sites in the second leukemic cells as in the first ones (Table 1) . Furthermore, we performed Southern blot using probes that lie in the vicinity of the integration sites in leukemic cells derived from mice ID2 and 4. The retroviral integrations near the C/EBPb gene were clearly detected by Southern blotting in the leukemic clones, suggesting that the clones in which Evi1 integrates near the C/EBPb gene command a majority with proliferative advantage ( Figure 1H ).
C/EBPb was overexpressed in the Evi1-leukemic cells
As the locus of integrations seemed to be too far from the genes to influence their expressions, we examined the messenger RNA (mRNA) expression levels of C/EBPb, Tmem189, LOC10043728, and Ptpn1, all of which are located near the integration site. A high expression level of C/EBPb, but not Tmem189, LOC10043728, or Ptpn1, was observed in the Evi1-leukemic cells ( Figure 2A -B and supplemental Figure 1 ). High C/EBPb mRNA levels were observed in 10 mice (ID2, 3, 4, 6, 7, 8, 11, 13, 15, and 21) , and the remaining mice showed slightly lower expression levels (ID1 and 5) but still higher than mock. There are 3 isoforms of C/EBPb, known as LAP*, LAP, and LIP, that arise from unique C/EBPb mRNA by differential initiation of translation ( Figure 2C ). To distinguish 3 isoforms, we performed western blotting for C/EBPb and confirmed high expression of all C/EBPb isoforms in the Evi1-leukemic cells ( Figure 2D ). High expression of C/EBPb was also observed in the Evi1-leukemic cells without retroviral integration near C/EBPb (ID 1, 5, 15, and 21). In contrast, C/EBPb expression was not observed in other leukemic cells expressing AML1-D171N, AML1-S291fs, 7 MLL/ENL, or RasGRP4. 21 Thus, high expression of C/EBPb was a characteristic feature of Evi1-leukemia ( Figure 2B ; P 5 .0046). To examine the possibility of transcriptional activation of C/EBPb by Evi1, we performed luciferase assays using 3.5 kb upstream of the C/ EBPb gene body. This area includes 3 predictive sequences as Evi1 binding sites (supplemental Figure 2A) . However, Evi1 did not activate the C/EBPb promoter in 293T and HeLa cell lines (supplemental Figure 2B) .
Expression of C/EBPb in murine hematopoietic stem cells and human leukemic patient samples
To examine the expression pattern of C/EBPb in normal hematopoietic cells, we performed real-time PCR for C/EBPb in cKit-positive, Sca1-positive, lineage-negative (KSL) cells, common myeloid progenitor (CMP) cells, megakaryocyte erythroid progenitor (MEP) cells, and granulocyte/macrophage progenitor (GMP) cells. Interestingly, expression of C/EBPb was higher in KSL cells than in CMP, MEP, or GMP cells ( Figure 3A ). In addition, we examined the Evi1 deficiency effect on mouse hematopoietic stem cells by analyzing the Evi1-deficient mice that we had made 22 (GSE11557. 1418901_at. The gene chip data are available on the GEO Web site). Although there was no statistical significance, expression of C/EBPb was decreased in the hematopoietic stem cells of the Evi1-deficient mice (P 5 .11; supplemental Figure 3) .
Next, we examined the relationship between Evi1 and C/EBPb in human samples. The information regarding patient samples is shown in supplemental Table 5 . Consistent with other reports, For personal use only. on July 23, 2017. by guest www.bloodjournal.org From we found that 14.6% of patients expressed a high level of Evi1. However, we did not find any correlation between Evi1 and C/EBPb mRNA expression in patients with AML (supplemental Figure 4) . Additional studies using published microarray data of larger cohorts showed no statistical correlation between Evi1 and C/EBPb expression in transcriptional levels (supplemental Figure 5) .
Therefore, we next performed western blotting for CEBPb on human AML samples. The BM cells of patients with lymphoma without BM invasion or primary immune thrombocytopenia were analyzed as controls ( Figure 3B ). The information about patient samples is shown in supplemental Table 6 . The protein analysis allowed us to evaluate expression of the 3 isoforms of C/EBPb individually. Interestingly, expression of these isoforms was high in some AML samples compared with control samples. Among the C/EBPb isoforms, LAP* and LIP were predominantly expressed in human AML samples. Expression of C/EBPb was not detected in CD34
1 cells from BM and PB of the control cells ( Figure 3C ). We also performed western blotting for Evi1 protein expression and C/EBPa expression in these samples. We quantitated the intensities of the bands of LAP*, LIP, Evi1, and b-actin by densitometry using Multi Gauge Version 3.0 software (Fujifilm). Expression of Evi1 closely correlated with that of LAP* and LIP in patients with AML at a protein level ( Figure 3D ).
LIP induces leukemic transformation of primary BM cells in vitro and AML in vivo
To examine the transforming activity of the 3 isoforms (LAP*, LAP and LIP), we performed a colony-replating assay. The expression plasmids were transfected into PLAT-E cells, and protein expression was examined by immunoblotting ( Figure 4A ). Although the LAP* cDNA contains 3 ATGs for all isoforms, it leads to expression of LAP* with a scarce amount of LAP and no LIP. The 3 isoforms were transduced in primary BM cells by retroviral transduction, and the transduced cells were cultured in methylcellulose with the defined cytokines. Although neither LAP* nor LAP showed the ability to transform primary BM cells, LIP induced transformation of the primary BM cells (Figure 4B-C) . Furthermore, we succeeded in making a LIP-expressing cell line, which was grown in a liquid culture medium, RPMI supplemented with 10% fetal calf serum and 5 ng/mL of IL-3 ( Figure 4D -E). We also established an Evi1-expressing cell line under the same culture condition for the LIPexpressing cell line ( Figure 4D,F) . Marker profiles of LIP and Evi1 leukemic cells in the liquid culture are shown in Figure 4G , both of which coincide with that of myeloid leukemia. Next, we examined the role of C/EBPb in leukemogenesis in vivo. Mouse BMT with C/EBPb were performed in the same way as for the Evi1-leukemia BMT model. 8 Infection efficiency and transplanted cell numbers are shown in supplemental Table 7 . Interestingly, transduction of LIP alone induced AML with long latencies of ;6 to 9 months ( Figure 5A-B) . On the other hand, LAP*-or LAP-expressing cells showed no engraftment.
LIP collaborates with Evi1 to induce AML in vivo
To clarify the relationship between Evi1 and C/EBPb in leukemogenesis in vivo, we performed Evi1-C/EBPb coexpressing BMT. For double infection, we mixed the virus carrying Evi1 (GFP) and one of the 3 viruses carrying LIP, LAP, or LAP* (Kusabira Orange) with an equal volume. The number of Evi1 and LIP double-positive cells gradually increased in the PB of the recipient mice ( Figure 5C-D) . Finally, the mice that had received the BM cells cotransduced with Evi1 and LIP went on to have AML ;4 to 5 months after the transplantation. The latencies were shorter than those of the mice that had received the BM cells expressing Evi1 alone or LIP alone ( Figure 6A and Table 2 ). This finding indicates that LIP accelerates the transforming capacity of Evi1 in vivo.
In contrast, the Evi1 and LAP double-positive cells showed no engraftment. Cotransduction of Evi1 and LAP into primary BM cells resulted in the development of Evi1-leukemia without Kusabira Orange expression in the recipient mice ( Figure 5C ). Although the latencies were slightly longer than those of the mice that had received the BM cells expressing Evi1 alone, the results were not statistically significant ( Table 2) . Only 1 mouse showed increased double-positive cells in the PB, and the mouse died at 251 days after BMT. Therefore, acceleration of the Evi1-leukemia by LAP was not identified in our model.
Cotransduction of Evi1 and LAP* into primary BM cells showed diverse results. Three of the mice died of the Evi1 and LAP* double-positive leukemia, 2 of the mice died of the Evi1-leukemia without Kusabira Orange expression, and the remaining mouse died of B-lineage acute lymphoblastic leukemia derived from recipient cells ( Figure 5C ). Although the average survival duration was slightly shorter than that of the mice which had received the BM cells expressing Evi1 alone, the result was not statistically significant (Table 2) .
LIP and LAP* collaborate with Evi1 to induce AML in vivo
Because the human AML with activated Evi1 predominantly expressed LIP and LAP* (Figure 3C ), we tried triple induction of Evi1, LAP*, and LIP into primary BM cells and performed BMT. For triple infection, we mixed the viruses carrying Evi1 (GFP), LIP (Kusabira Orange), and LAP* (Kusabira Orange) with an equal volume. Interestingly, the triple induction induced AML with shorter latencies than that of Evi1 alone or Evi1/LIP double induction ( Figure 6A and Table 2 ). We confirmed simultaneous expression of Evi1, LAP*, and LIP in the Evi1/LAP*/LIP-leukemic cells by immunoblotting ( Figure 6B ). These results suggest that LAP* provides a synergistic effect on the development of leukemia with high Evi1 expression in the presence of LIP. Although the direct interaction of Evi1 and C/EBPb have been reported in is a polyclonal antibody raised against a peptide mapping at the C-terminus of the C/EBPb of rat origin. The spleen cells were derived from Evi1-leukemia mice, AML1-related leukemia mice (AML1-D171N and AML1-S291fs), MLL/ENL-leukemia mice, RasGRP4-leukemia mice, and a control normal mouse. Mice ID numbers are shown at the top of panels. Plus marks indicate retroviral integration near the C/EBPb.
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To identify the key factors in Evi1-LIP leukemogenesis, we examined the expression of several genes in the leukemic cells induced by Evi1 alone, LIP alone, and Evi1 plus LIP (supplemental Figure 6 ). We identified a high expression of GATA2 and Pbx1 in the Evi1-leukemia, consistent with previous reports. 24, 25 Interestingly, expression of Dnmt3a increased in the LIP-leukemic cells. LIP did not inhibit expression of C/EBPa.
C/EBPb excision does not inhibit the development of Evi1-induced leukemia in vivo
To assess the effect of C/EBPb excision in Evi1-related leukemia, we transduced Evi1 into the BM cells derived from the Mx-Cre; C/EBPb fl/fl mice and then performed BMT ( Figure 7A ). At the startup of this experiment, we planned to delete C/EBPb by injecting pIpC after development of Evi1-leukemia. However, we confirmed that excision of the C/EBPb locus had already occurred in a part of the BM cells on infection of the Evi1 retrovirus before transplantation ( Figure 7B ), which suggests partial activation of the Mx promoter by retrovirus infection-induced interferon secretion without pI-pC injection. We transplanted all of the infected cells, including both C/EBPb fl/fl cells and C/EBPb 2/2 cells, into the recipient mice. The percentages of GFP-positive cells in the PB were higher in the mice that received the BM cells derived from the Mx-Cre;C/EBPb fl/fl mice than the mice that received the BM cells derived from the C/EBPb fl/fl mice ( Figure 7C ). Interestingly, the C/EBPb 2/2 cells increased without pIpC injection, parallel with the percentages of GFP-positive cells ( Figure 7D ). Most of the Evi1-leukemia derived from the MxCre;CEBPb fl/fl cells lost the C/EBPb locus ( Table 3) . As all of the genotyping PCR contained a wild-type band by contamination of the wild-type cells derived from the recipient, we sorted GFP-positive BM cells and performed genotyping PCR to avoid contamination of wild-type cells ( Figure 7E ). There were 5 of 6 examined leukemic cells that had only deleted alleles. The mean survival duration of the mice was slightly shorter than that of the mice which had received the wild-type BM cells expressing Evi1 (261.8 days vs 282.9 days); however, this was not statistically significant ( Figure 7F ). These results indicate that excision of C/EBPb does not inhibit the development of Evi1-induced leukemia and that C/EBPb is not essential for Evi1-induced transformation. Because a previous study from another group has shown the relevance of diminished C/EBP activity to leukemia with an erythroid phenotype, in which bcr-abl induces erythroleukemia in CEBPa 2/2 mice, 26 we stained the Evi1-induced leukemic cells with Ter119 and confirmed that the leukemic cells were negative for Ter119 regardless of C/EBPb genotype (supplemental Figure 7) .
Next, we attempted to delete the C/EBPb locus by pI-pC injection before transplantation. However, the C/EBPb locus was not completely ablated (supplemental Figure 8) . In this experiment, we confirmed that the deleted band was enhanced after cytokine stimulation and retroviral infection. These results suggest that a successful retroviral infection induced interferon secretion and C/EBPb depletion, and then the C/EBPb-deleted clones generated Evi1-leukemia. Consistent with these findings, the percentages of GFP-positive cells correlated with enhancement of the deleted band in the genotyping PCR of PB cells ( Figure 7D ).
LAP* and LAP inhibit the development of Evi1-induced leukemia
To examine the role of the 3 isoforms of C/EBPb (LAP*, LAP, and LIP) in the development of Evi1-induced leukemia, we transduced each isoform into the Evi1-induced leukemic cells derived from C/EBPb 2/2 cells ( Figure 7G ). For this experiment, we used BM cells derived from mice ID5 and ID2 ( Figure 7E ). After retroviral infection, we sorted the double-positive cells (Evi1-GFP/C/EBPbKusabira Orange) and transplanted the cells into recipient mice. Interestingly, only recipients of Evi1-induced leukemia cells with LIP overexpression showed leukemia development with a doublepositive (Evi11, LIP1) population in the recipients, whereas LAP* or LAP transduction did not yield such a population, and the recipient mice were healthy for 3 months ( Figure 7H-I) . In 2 mice (ID LAP*-1 and ID LAP-1), we confirmed engraftment of GFP (Evi1)-positive but Kusabira Orange (LAP* or LAP)-negative leukemic cells, and LAP-1 died with Evi1-single-positive leukemia at day 97. These results indicate that LIP accelerates the development of Evi1-induced leukemia, whereas LAP* and LAP inhibit such development.
Discussion
The cooperation of Evi1 and LIP that we showed in this study is a novel mechanism in Evi1-induced leukemogenesis. In leukemia research, it is known that C/EBPb is recurrently targeted by IGH translocations in B-cell precursor acute lymphoblastic leukemia, 27 and it regulates transcription factors critical for the proliferation and survival of multiple myeloma cells. 28 Furthermore, expression of LIP is increased in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive myeloid leukemic cells. 29 On the other hand, C/EBPb was shown to be upregulated during ATRAinduced differentiation of acute promyelocytic leukemia cells, and it was considered as a potential therapeutic target in leukemia for granulocytic differentiation. 30 Taken together, C/EBPb has leukemia suppressor-like activity in acute promyelocytic leukemia, and it also has critical oncogenic functions in FLT3-ITD leukemia, B-lineage acute lymphoblastic leukemia, and multiple myeloma.
To make clear the role of C/EBPb in leukemogenesis, we need to distinguish 3 isoforms of C/EBPb: LAP*, LAP, and LIP. All of these isoforms arise from unique C/EBPb mRNA by differential initiation of translation.
31,32 LAP* and LAP are transactivators, and the former has additional 23 N-terminal amino acids. LIP, a short isoform, lacks the transactivation domain and represses the transcriptional activity of LAP* and LAP.
33
In our study, we demonstrated that overexpression of LIP alone caused the transformation of primary BM cells in vitro and induced the development of AML in vivo with long latencies. Our study is the first that provides direct evidence of the role of LIP in leukemogenesis in vivo. On the other hand, neither LAP*-nor LAP-expressing cells engrafted in recipient mice. These findings imply that overexpression of LAP* or LAP does not contribute to leukemic transformation of the BM cells, which may be related to their potential to induce granulocytic differentiation. 34, 35 However, we observed that the Evi1-induced leukemic cells expressed not only LIP but also LAP* and LAP in the mouse model. Furthermore, expression of Evi1 correlated closely with expression of both LAP* and LIP in patients with AML. Consistent with these findings, triple induction of Evi1, LAP*, and LIP induced AML with shorter latencies than that of double induction of Evi1 and LIP. These results suggest that LIP may not always antagonize but may cooperate with LAP* depending on the cellular milieu, as is the case with the development of Evi1-leukemia.
LIP can act as an inhibitor of the other C/EBPs, including C/EBPa, by forming nonfunctional heterodimers. C/EBPa-p30, a short isoform, also has a dominant-negative function on C/EBPap42. Recent studies have suggested that the loss of function or expression of C/EBPa promotes the development of AML. 36 Furthermore, the ability of C/EBPa-p30 to induce AML has been shown in a mouse model. 37, 38 In the same way as C/EBPa-p30, LIP may dominantly inhibit C/EBPa function and subsequently contribute to the development of AML. Two-step leukemogenesis has been suggested in several clinical investigations [39] [40] [41] [42] and murine BMT models. [43] [44] [45] According to these reports, leukemia-related mutations are classified into 2 groups: class I and class II mutations. Class I mutations include proliferative or antiapoptotic gene mutations such as c-Kit, BCR/ABL, or FLT3-ITD. Class II mutations include dominant negative mutations of transcription factors involved in the differentiation of hematopoietic cells, such as AML1/ETO, PML/RARa, or C/EBPa. As LIP has a dominant negative effect on LAP* and LAP, LIP might be included in a class II gene, which blocks differentiation of hematopoietic cells. Therefore, in this context, Evi1 may act as a class I gene. Consistently, Evi1 also collaborates with AML1-D171N, which is recognized as a class II mutation in leukemogenesis. 7 Although mutations of C/EBPb are rare events in human samples, 46 extensive and careful research including that of translational control factors 47 For personal use only. on July 23, 2017. by guest www.bloodjournal.org From may yield valuable information that will allow us to clarify the role of C/EBPb in leukemogenesis. We also identified a subgroup of patients with AML, which shows undetectable Evi1 expression but exhibits high C/EBPb expression. C/EBPb may collaborate with other factors in this type of leukemia.
In our experiments, C/EBPb excision did not inhibit the development of Evi1-induced leukemia. On the other hand, serial transduction of LAP* and LAP inhibits the development of Evi1-induced leukemia, whereas LIP accelerates such development. Given a potential tumor-suppressive property of LAP*/LAP on which the transforming activity of LIP may depend, one possibility is that loss of LAP*/LAP dominates the phenotype of C/EBPb-deleted mice when all of the 3 isoforms are deleted by excision of C/EBPb alleles. Therefore, we conclude that translational control to reduce expression of LIP is required when we consider C/EBPb as a therapeutic target in the setting of translation to clinical application. Conditional excision of each isoform may be informative to clarify the role of C/EBPb in leukemogenesis.
Interestingly, we observed higher mRNA expression of C/EBPb in hematopoietic stem cells than in progenitor cells. On the other hand, it has been shown that a significant number of C/EBPbdeficient mice die perinatally and that hematopoietic progenitor cells of surviving C/EBPb-deficient mice respond imperfectly to GM-CSF and G-CSF, 34 which suggests an important role of C/EBPb in both hematopoietic stem cells and progenitor cells in mice. However, we did not detect C/EBPb protein in human CD34 1 cells.
Therefore, the role of C/EBPb in human hematopoietic stem cells remains to be elucidated. It is a puzzle to us why the mice showed a high expression of C/EBPb without retroviral integration near its locus. Although we examined the possibility of transcriptional activation of C/EBPb by Evi1, Evi1 had no potential to activate the C/EBPb promoter region. Sauvageau and colleagues 48 used common retroviral integration sites to find out that Gfi1 was highly expressed in 14 leukemic mice but that only 7 of those showed retroviral integrations near Gfi1. The mechanism of Gfi1 expression in 7 mice without retroviral integration remains to be elucidated. However, their approach succeeded in identification of the candidate genes as cell type-specific cancer genes in leukemia. 48 We and another group also observed similar results.
7,49
Therefore, we believe that insertional mutagenesis is one of the powerful tools to predict a cell-specific region containing genes responsible for initiation or progression of leukemia. Overexpression of the genes in the absence of nearby retroviral integrations might be caused by the activation of some upstream regulators in the same pathway or might be associated with the higher-order architecture of genome DNA. C/EBPb forms a transcriptional complex with PRDM16, also named a MDS1/EVI1-like gene, in the transmission of myoblasts to brown fat.
11 PRDM16 is a zinc finger transcription factor with an N-terminal PR domain and belongs to the gene family of Evi1. PRDM16 is also involved in chromosomal translocations in human leukemias. 50 Similar to Evi1, this gene is expressed exclusively in the hematopoietic stem and progenitor cells. 51 Although we identified the collaboration of Evi1 with C/EBPb in leukemogenesis, we did not detect the direct interaction of the 2 factors in the leukemic cells. Therefore, the precise mechanism of how Evi1 collaborates with C/EBPb in leukemogenesis is currently unclear and needs to be examined.
